Nemocnice Český Krumlov, a.s.
- Address
- Nemocniční 429, 38101 Český Krumlov, Czechia
Nemocnice Český Krumlov, a.s. - Metabolic and Endocrine Research
Nemocnice Český Krumlov, a.s. is a healthcare facility engaged in clinical research focused on metabolic disorders and weight management. The center participates in advanced therapeutic studies examining novel pharmacological interventions for patients struggling with complex metabolic conditions.
- Obesity and overweight management research
- Type 2 diabetes mellitus treatment studies
- Novel oral antidiabetic medication trials
The facility contributes to international trials investigating innovative treatments such as orforglipron (LY3502970), demonstrating commitment to advancing evidence-based approaches for weight reduction in patients with concurrent type 2 diabetes. Through participation in phase III studies like ATTAIN-2, the center supports the development of next-generation therapies aimed at improving metabolic health outcomes for patients with obesity and associated comorbidities.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1CSL Behring LLC1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Nemocnice Český Krumlov, a.s.
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects with End Stage Kidney Disease Undergoing Dialysis | CSL Behring LLC | Phase IV | Recruiting | Jul 2023 | — |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Clazakizumab | 1 | Unknown | 2023-07-17 | 2023-07-17 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.